AlphAIalphai — Financial news for AI agents
3blmedia.comJUN 105 min read$CVSBullishMed

CVS Caremark Delivers Affordability and Access to GLP

CVS Health’s CVS Caremark said it will update commercial formularies to expand GLP-1 coverage. According to the company, Zepbound (tirzepatide) will be reintroduced as a preferred option on Oct. 1, 2026, and the “new-to-market” block on Foundayo (orforglipron) will be removed where plans approve coverage, effective June 1, 2026. CVS cited efforts to improve affordability and access for members.

AI DeskJune 10, 2026
Source · 3blmedia.com
AI analysis
Relevance
7/10
Novelty
6/10
Actionability
Med
Sentiment · $CVS
Bullish
Timing
Coverage changes effective June 1, 2026 (Foundayo) and Oct 1, 2026 (Zepbound preferred).
Market alignment
Supports a constructive view of CVS Caremark’s GLP-1 affordability strategy and formulary competitiveness.
Why this matters for $CVS

Formulary expansion for GLP-1s can improve CVS Caremark member access and support PBM economics, but near-term financial impact is uncertain.

Relevance context

CVS Caremark will reintroduce Zepbound to commercial formularies (preferred option Oct 1, 2026) and remove the new-to-market block on Foundayo where approved.

Price-impact prediction

Moderate positive bias for CVS on expectations of improved GLP-1 coverage/retention; magnitude likely limited without disclosed financial terms.

Background

CVS Caremark manages drug formularies for commercial plans and negotiates medication costs with manufacturers; GLP-1 coverage has been constrained by high prices.

Why it matters

By adding Zepbound as a preferred option and easing coverage restrictions on an oral GLP-1 (Foundayo) where approved, CVS aims to increase access and affordability while maintaining sustainable benefit programs.

Market relevance

A concrete PBM formulary update with dated implementation windows that can influence GLP-1 access, utilization, and payer economics.

Market effects

Sector

Signals PBM willingness to expand GLP-1 coverage while negotiating affordability, potentially intensifying competitive pressure across PBMs and payers.

Regional

Primarily US commercial plan dynamics; could affect US GLP-1 access and utilization patterns.

Global

Limited direct global relevance; GLP-1 pricing/access dynamics are largely US payer-driven here.

Alternative perspectives

Contrarian view

Formulary changes may shift mix without guaranteeing net margin improvement if rebates/pricing concessions compress economics.

Overlooked factors

Plan sponsors can customize template formularies, so adoption rates and actual utilization lift may vary widely versus the headline suggests.

Key entities

  • business unit
    CVS Caremark

    CVS Health’s pharmacy benefits manager updating commercial formularies for GLP-1 weight management drugs.

  • drug
    Zepbound (tirzepatide)

    GLP-1 therapy being reintroduced as a covered preferred option in CVS Caremark commercial formularies effective Oct 1, 2026.

  • drug
    Foundayo (orforglipron)

    Oral GLP-1 therapy; CVS will remove the new-to-market block effective June 1, 2026 where plans approve coverage.

Read at source← All news

Related articles

JUL 11
$CVSMed

Jim Cramer: “The Real Bull Market” Is Happening in Health Insurance. CVS Is One of the Biggest Winners as Walgreens “Basically Disappears”

CNBC host Jim Cramer said the “real bull market” is in health insurance, citing managed-care pricing power. He highlighted CVS Health, whose Aetna operating income rose 53% and Q1 adjusted EPS was $2.57 vs $2.21 consensus, with guidance raised to $7.30-$7.50. He also cited UNH and HUM results and expects pricing to stay double-digit.

yahoo.com5 min
JUL 6
$CVSMed

CT And CVS Settle Multistate Insulin Claims Case For $35M

Connecticut and other states settled multistate Medicaid insulin-pen false-claims allegations with CVS Pharmacy for $35M. Up to $25.1M goes to participating states’ Medicaid programs; Connecticut’s Medicaid share is $1.09M (state-only just under $634k), per AG William Tong. Allegations cover 2010–2020 over-dispensing and premature refills; CVS said insulin billing is complex.

ctnewsjunkie.com3 min
JUL 2
$CVSMed

11 new vet rules including £21 cap for dog and cat owners

The UK Competition and Markets Authority (CMA) set final reforms for veterinary services, including legally binding prescription-fee caps (£21 for the first medicine, £12.50 for additional items), required written estimates for treatments expected to cost £500+ (except emergencies), and published price lists and price-comparison data. CVS Group said it supports the amended cap. Changes are due to start from 23 September for larger chains, with wider rollout by Dec 2026/Mar 2027.

getsurrey.co.uk4 min
JUN 27
$CVSMed

States seek to lower drug prices by targeting companies that manage them for health plans

States are moving to lower prescription drug prices by regulating pharmacy benefit managers (PBMs), which administer drug coverage for insurers and negotiate with manufacturers. Laws in at least a dozen states this year would cap PBM compensation, set minimum pharmacist payments, and require more disclosure. Tennessee’s 2028 ban on PBM retail operations is being challenged by CVS, which has 136 pharmacies there.

kshb.com6 min
JUN 27
$CVSMed

CVS Just Turned Its 9,000 Pharmacies Into a GLP-1 Delivery Machine. 1 Top Wall Street Analyst Thinks That's a Reason to Buy the Stock

CVS Health said it will launch a GLP-1 support program at more than 9,000 U.S. pharmacies, offering $49 virtual visits for clinician evaluation and prescriptions. According to CVS, GLP-1 drug costs start at $25/month with insurance, $50/month for eligible Medicare patients, or $149/month without insurance, plus one-on-one support. Bank of America analyst Allen Lutz raised his price target to $110 from $100.

fool.com6 min